About: Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $6.39 (+15.14%)
EIKN NASDAQ Eikon Therapeutics, Inc. Common Stock
Eikon Therapeutics, Inc. Common Stock share price
Atividade de preço de EIKN
Último preço
$ 6,390
Variação (24h)
0,84 USD (15,14%)
Volume
658.15K
Volume (média 4 sem.)
-
Abertura
$ 5,69
Variação do dia
$ 5,36 - $ 6,42
Fechamento anterior
$ 5,55
Último negócio
04 Nov, 9:08 pm GMT+0
Atrasado
04 Nov, 9:08 pm GMT+0
EIKN price performance
Atrasado
04 Nov, 9:08 pm GMT+0
EIKN details
quote.marketSignals